Last reviewed · How we verify

NOVA22007 (Ciclosporin 0.1%)

Santen SAS · Phase 3 active Small molecule

NOVA22007 (Ciclosporin 0.1%) is a Calcineurin inhibitor Small molecule drug developed by Santen SAS. It is currently in Phase 3 development for Dry eye disease (keratoconjunctivitis sicca).

Ciclosporin is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.

Ciclosporin is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye. Used for Dry eye disease (keratoconjunctivitis sicca).

At a glance

Generic nameNOVA22007 (Ciclosporin 0.1%)
SponsorSanten SAS
Drug classCalcineurin inhibitor
TargetCalcineurin (protein phosphatase 2B)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

Ciclosporin binds to cyclophilin and inhibits calcineurin, a phosphatase required for T-cell receptor signaling and IL-2 production. This suppresses the activation and proliferation of T-lymphocytes in ocular tissues, reducing inflammation. NOVA22007 is a 0.1% ophthalmic formulation designed for improved ocular penetration and therapeutic effect in dry eye disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NOVA22007 (Ciclosporin 0.1%)

What is NOVA22007 (Ciclosporin 0.1%)?

NOVA22007 (Ciclosporin 0.1%) is a Calcineurin inhibitor drug developed by Santen SAS, indicated for Dry eye disease (keratoconjunctivitis sicca).

How does NOVA22007 (Ciclosporin 0.1%) work?

Ciclosporin is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.

What is NOVA22007 (Ciclosporin 0.1%) used for?

NOVA22007 (Ciclosporin 0.1%) is indicated for Dry eye disease (keratoconjunctivitis sicca).

Who makes NOVA22007 (Ciclosporin 0.1%)?

NOVA22007 (Ciclosporin 0.1%) is developed by Santen SAS (see full Santen SAS pipeline at /company/santen-sas).

What drug class is NOVA22007 (Ciclosporin 0.1%) in?

NOVA22007 (Ciclosporin 0.1%) belongs to the Calcineurin inhibitor class. See all Calcineurin inhibitor drugs at /class/calcineurin-inhibitor.

What development phase is NOVA22007 (Ciclosporin 0.1%) in?

NOVA22007 (Ciclosporin 0.1%) is in Phase 3.

What are the side effects of NOVA22007 (Ciclosporin 0.1%)?

Common side effects of NOVA22007 (Ciclosporin 0.1%) include Ocular irritation/burning, Conjunctival hyperemia, Foreign body sensation, Blurred vision.

What does NOVA22007 (Ciclosporin 0.1%) target?

NOVA22007 (Ciclosporin 0.1%) targets Calcineurin (protein phosphatase 2B) and is a Calcineurin inhibitor.

Related